BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31600778)

  • 1. Mutations in CHCHD2 cause α-synuclein aggregation.
    Ikeda A; Nishioka K; Meng H; Takanashi M; Hasegawa I; Inoshita T; Shiba-Fukushima K; Li Y; Yoshino H; Mori A; Okuzumi A; Yamaguchi A; Nonaka R; Izawa N; Ishikawa KI; Saiki H; Morita M; Hasegawa M; Hasegawa K; Elahi M; Funayama M; Okano H; Akamatsu W; Imai Y; Hattori N
    Hum Mol Genet; 2019 Dec; 28(23):3895-3911. PubMed ID: 31600778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease.
    Fan L; Zhang S; Li X; Hu Z; Yang J; Zhang S; Zheng H; Su Y; Luo H; Liu X; Fan Y; Sun H; Zhang Z; Miao J; Song B; Xia Z; Shi C; Mao C; Xu Y
    Brain Pathol; 2023 May; 33(3):e13124. PubMed ID: 36322611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2.
    Torii S; Arakawa S; Sato S; Ishikawa KI; Taniguchi D; Sakurai HT; Honda S; Hiraoka Y; Ono M; Akamatsu W; Hattori N; Shimizu S
    EMBO Mol Med; 2023 Sep; 15(9):e17451. PubMed ID: 37578019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological characterization of a novel mouse model expressing the PD-linked CHCHD2-T61I mutation.
    Kee TR; Wehinger JL; Gonzalez PE; Nguyen E; McGill Percy KC; Khan SA; Chaput D; Wang X; Liu T; Kang DE; Woo JA
    Hum Mol Genet; 2022 Nov; 31(23):3987-4005. PubMed ID: 35786718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHCHD2 harboring Parkinson's disease-linked T61I mutation precipitates inside mitochondria and induces precipitation of wild-type CHCHD2.
    Cornelissen T; Spinazzi M; Martin S; Imberechts D; Vangheluwe P; Bird M; De Strooper B; Vandenberghe W
    Hum Mol Genet; 2020 May; 29(7):1096-1106. PubMed ID: 32068847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and pharmacologic p32-inhibition rescue CHCHD2-linked Parkinson's disease phenotypes in vivo and in cell models.
    Tio M; Wen R; Choo CN; Tan JB; Chua A; Xiao B; Sundaram JR; Chan CHS; Tan EK
    J Biomed Sci; 2024 Feb; 31(1):24. PubMed ID: 38395904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson's disease.
    Liu X; Wang Q; Yang Y; Stewart T; Shi M; Soltys D; Liu G; Thorland E; Cilento EM; Hou Y; Liu Z; Feng T; Zhang J
    Acta Neuropathol Commun; 2021 Mar; 9(1):37. PubMed ID: 33685516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHCHD10 is involved in the development of Parkinson's disease caused by CHCHD2 loss-of-function mutation p.T61I.
    Mao C; Wang H; Luo H; Zhang S; Xu H; Zhang S; Rosenblum J; Wang Z; Zhang Q; Tang M; Shepard MJ; Wang X; Wang Y; Zhuang Z; Shi C; Xu Y
    Neurobiol Aging; 2019 Mar; 75():38-41. PubMed ID: 30530185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHCHD2 Thr61Ile mutation impairs F1F0-ATPase assembly in
    Chen X; Lin Y; Zhang Z; Tang Y; Ye P; Dai W; Zhang W; Liu H; Peng G; Huang S; Qiu J; Guo W; Zhu X; Wu Z; Kuang Y; Xu P; Zhou M
    Neural Regen Res; 2024 Jan; 19(1):196-204. PubMed ID: 37488867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.
    Shammas MK; Huang TH; Narendra DP
    Biochem Soc Trans; 2023 Apr; 51(2):797-809. PubMed ID: 37021679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c.
    Meng H; Yamashita C; Shiba-Fukushima K; Inoshita T; Funayama M; Sato S; Hatta T; Natsume T; Umitsu M; Takagi J; Imai Y; Hattori N
    Nat Commun; 2017 Jun; 8():15500. PubMed ID: 28589937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of induced pluripotent stem cell line (ZZUi007-A) from a 52-year-old patient with a novel CHCHD2 gene mutation in Parkinson's disease.
    Wang Y; Wang Z; Sun H; Mao C; Yang J; Liu Y; Liu H; Zhang S; Zhang J; Xu Y; Shi C
    Stem Cell Res; 2018 Oct; 32():87-90. PubMed ID: 30237140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homeostatic p62 levels and inclusion body formation in CHCHD2 knockout mice.
    Sato S; Noda S; Torii S; Amo T; Ikeda A; Funayama M; Yamaguchi J; Fukuda T; Kondo H; Tada N; Arakawa S; Watanabe M; Uchiyama Y; Shimizu S; Hattori N
    Hum Mol Genet; 2021 Apr; 30(6):443-453. PubMed ID: 33631794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction.
    Zhou W; Ma D; Sun AX; Tran HD; Ma DL; Singh BK; Zhou J; Zhang J; Wang D; Zhao Y; Yen PM; Goh E; Tan EK
    Hum Mol Genet; 2019 Apr; 28(7):1100-1116. PubMed ID: 30496485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHCHD2 gene mutations in familial and sporadic Parkinson's disease.
    Shi CH; Mao CY; Zhang SY; Yang J; Song B; Wu P; Zuo CT; Liu YT; Ji Y; Yang ZH; Wu J; Zhuang ZP; Xu YM
    Neurobiol Aging; 2016 Feb; 38():217.e9-217.e13. PubMed ID: 26705026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.
    Jinn S; Drolet RE; Cramer PE; Wong AH; Toolan DM; Gretzula CA; Voleti B; Vassileva G; Disa J; Tadin-Strapps M; Stone DJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2389-2394. PubMed ID: 28193887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.